



Dr. rer.nat Elke Hiendlmeyer

Clinical Trials Unit · Dept. Direktion

Kontakt

Dr. rer.nat Elke Hiendlmeyer
Switzerland

T 0041-71-494 3598
elke.hiendlmeyer@kssg.ch

Bereiche

Clinical Trials Unit

Publikationen (7)

Mey U, Ruefer A, Ziske C, Knauf W, Cathomas R, von Moos R, Hitz F, Sauter R, Hiendlmeyer E, Cantoni N, Bargetzi M, Fischer N, Doerfel S, Brugger W, Schwarb H, Pederiva S, Schwarzer A, Dechow T, Jehner P, Rauh J, Taverna C, Schmid M, Schmidt-Hieber M, Driessen C. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma - a phase II trial. *Br J Haematol* 2016

Wassermann S, Kirchner T, Brabletz T, Merkel S, Reu S, Kriegl L, Haynl A, Hlubek F, Horst D, Palmqvist R, Hiendlmeyer E, Scheel S, Jung A. p16INK4a is a beta-catenin target gene and indicates low survival in human colorectal tumors. *Gastroenterology* 2009; 136:196-205.e2.

Beiter K, Hiendlmeyer E, Brabletz T, Hlubek F, Haynl A, Knoll C, Kirchner T, Jung A. beta-Catenin regulates the expression of tenascin-C in human colorectal tumors. *Oncogene* 2005; 24:8200-4.

Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A, Kirchner T. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. *Cells Tissues Organs (Print)* 2005; 179:56-65.

Hiendlmeyer E, Kirchner T, Brabletz T, Reuning U, van Beest M, Knoll C, Koch C, Dimmler A, Haynl A, Hlubek F, Wassermann S, Regus S, Jung A. Beta-catenin up-regulates the expression of the urokinase plasminogen activator in human colorectal tumors. *Cancer Res* 2004; 64:1209-14.

Ruckert S, Kirchner T, Brabletz T, Rüschoff J, Koch C, Haynl A, Dietmaier W, Beyser K, Oswald U, Brueckl W, Hiendlmeyer E, Jung A. T-cell factor-4 frameshift mutations occur frequently in human microsatellite instability-high colorectal carcinomas but do not contribute to carcinogenesis. *Cancer Res* 2002; 62:3009-13.

Stoehr R, Hartmann A, Hiendlmeyer E, Mürle K, Wieland W, Knuechel R. Oligoclonality of early lesions of the urothelium as determined by microdissection-supported genetic analysis. *Pathobiology* 2000; 68:165-72.

Projekte (1)

An open, multicentric phase II trial to evaluate the efficacy and safety of Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line therapy for patients with relapsed or refractory multiple myeloma

Klinische Forschung - 17.02.2012 - 17.07.2014

Automatisch geschlossen

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch